Order Article Reprints

Mikulski D, Robak P, Perdas E, Węgłowska E, Łosiewicz A, Dróżdż I, Jarych D, Misiewicz M, Szemraj J, Fendler W, et al. Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib. Journal of Clinical Medicine. 2022; 11(1):112. https://doi.org/10.3390/jcm11010112

Mikulski, Damian, Paweł Robak, Ewelina Perdas, Edyta Węgłowska, Aleksandra Łosiewicz, Izabela Dróżdż, Dariusz Jarych, Małgorzata Misiewicz, Janusz Szemraj, Wojciech Fendler, and et al. 2022. "Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib" Journal of Clinical Medicine 11, no. 1: 112. https://doi.org/10.3390/jcm11010112

Mikulski, D., Robak, P., Perdas, E., Węgłowska, E., Łosiewicz, A., Dróżdż, I., Jarych, D., Misiewicz, M., Szemraj, J., Fendler, W., & Robak, T. (2022). Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib. Journal of Clinical Medicine, 11(1), 112. https://doi.org/10.3390/jcm11010112